MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Medtech in a Minute: Dexcom's Snafu, a VR Surgical Robot, and More Image by OpenClipart-Vectors on Pixabay
We know your time is precious so we've drilled down the three most important medtech stories from the past week. But feel free to click the headline to read beyond the blurb.

Medtech in a Minute: Dexcom's Snafu, a VR Surgical Robot, and More

There's a cool new robot you should know about, and ViewRay has friends in high places. But first, Dexcom learns a valuable customer service lesson.

Dexcom Learns a Valuable Lesson 

A major server outage rattled Dexcom customers – particularly parents of diabetic children – over the U.S. Thanksgiving holiday weekend. But most were not as mad about the technology glitch as they were about the company's lack of communication about the issue. Dexcom has since fixed the problem and promised to communicate better with customers going forward.

Vicarious Surgical Scores Breakthrough Designation for Surgical Robot

Vicarious Surgical is now the first to receive a breakthrough device designation from FDA for a robotically-assisted surgical device. What makes this new robot so special? Virtual reality.

ViewRay Inks Deals with Elekta and Medtronic

ViewRay has signed a non-binding memorandum of understanding with both Elekta and Medtronic. Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay, and Medtronic has agreed to invest in a minority interest in the company. ViewRay and Elekta plan to advance the knowledge and use of MR-guided radiation therapy. ViewRay and Medtronic plan to explore the clinical benefits of the MRIdian MR-guided radiation therapy system.

TAGS: News
Hide comments
account-default-image

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish